We Give Shareholders a Voice

TransEnterix, Inc. Information Request Form

Levi & Korsinsky announces the filing of a class action lawsuit in the USDC for the Eastern District of North Carolina on behalf of shareholders of TransEnterix, Inc. (NYSE MKT: TRXC) who purchased shares between February 10, 2016 and May 10, 2016.

TransEnterix developed The SurgiBot ™ System, a surgical platform designed to be minimally invasive and allow for multiple instruments to be introduced and deployed through an incision. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that (a) there were deficiencies within the Company’s 510(k) application to the Food and Drug Administration which undermined the likelihood that the SurgiBot would receive FDA clearance; (b) that as a result of these deficiencies, TransEnterix would be unable to commercialize the SurgiBot in 2016; and (c) consequently, the Company’s ability to obtain approval for and commercialize its other robotic surgery platforms in the U.S. would be impaired.

If you suffered a loss in TransEnterix you have until August 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

To receive more information, please fill out the form.

Request More Information

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

This letter confirms that you have retained Levi & Korsinsky, LLP to represent you as a named plaintiff in a shareholder action involving TransEnterix, Inc.

We agree to advance all expenses in the litigation, which means that you are not liable to pay any of the expenses of the lawsuit, whether attorneys' fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys' fees or costs. Should we obtain a favorable result, we may ask the court to award us compensation to be paid by the defendants or as a portion of any class benefit, but, again, we will never ask you to directly pay any of the costs of this litigation.

As the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. During the course of this litigation, we may employ and/or work with other law firms to prosecute your case.

We look forward to representing you and other TransEnterix, Inc. shareholders.


Levi & Korsinsky,LLP

Joseph Levi

AGREED: Sign Name Clear